Skip to content

Exploring the metabolic profile of neuroendocrine tumors

Exploring the metabolic profile of neuroendocrine tumors - Indol

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON43011
Enrollment
210
Registered
2016-09-27
Start date
2016-10-07
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kanker neuroendocrine tumor

Interventions

indol profile
LC-MS/MS
neuroendocrine tumors

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for all subjects: - written informed consent - age above 18 years Inclusion criteria for patients with a NET: (one of these) - histologically proven NET, with or without treatment for the NET - a diagnosis made by a dedicated NET specialist based on a combination of physical symptoms and signs, imaging and laboratory values. Inclusion criteria for healthy subjects: - Matching in age (plus or minus 3 years) and sex with one of the included NET patients. Data of healthy subjects could also be used from the SERT-study, if the subject meets the criteria mentioned above.

Exclusion criteria

Exclusion criteria: Exclusion criteria for all subjects: - Use of drugs or food supplements that interact with the serotonin-metabolism; all serotonin re-uptake inhibitors, psychotrophic drugs, (other antidepressants; tricyclic antidepressants, MAO-inhibitors, mirtazapin, bupropion, venlafaxin, duloxetin, anxiolytic, antipsychotic and anticonvulsive drugs). - Drug abuse in the last 8 weeks. - Use of >= 14 alcoholic consumptions a week for women. - Use of >= 21 alcoholic consumptions a week for men. Exclusion criteria for healthy subjects: - Having a neuroendocrine tumor or neuroendocrine carcinoma from any grade and location in present or in history. - Having a malignancy. - Having an auto-immune disease. - Having an infection. - Having renal impairment. - Use of interferon.

Design outcomes

Primary

MeasureTime frame
In this exploratory study we will measure the indol profile in patients with a foregut NET, mid- and hindgut NET, and healthy volunteers at the time of diagnosis and during follow up and treatment in plasma and urine.

Secondary

MeasureTime frame
In addition, levels of catecholamines and metabolites in these three groups will be determined.

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)